Related Experiment Video
Updated: Aug 19, 2026

Artificial RNA Polymerase II Elongation Complexes for Dissecting Co-transcriptional RNA Processing Events
Published on: May 13, 2019
Distinction and relationship between elongation rate and processivity of RNA polymerase II in vivo
1Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts 02115, USA.
Abstract:
A number of proteins and drugs have been implicated in the process of transcriptional elongation by RNA polymerase (Pol) II, but the factors that govern the elongation rate (nucleotide additions per min) and processivity (nucleotide additions per initiation event) in vivo are poorly understood. Here, we show that a mutation in the Rpb2 subunit of Pol II reduces both the elongation rate and processivity in vivo. In contrast, none of the putative elongation factors tested affect the elongation rate, although mutations in the THO complex and in Spt4 significantly reduce processivity. The drugs 6-azauracil and mycophenolic acid reduce both the elongation rate and processivity, and this processivity defect is aggravated by mutations in Spt4, TFIIS, and CTDK-1. Our results suggest that, in vivo, a reduced rate of Pol II elongation leads to premature dissociation along the chromatin template and that Pol II processivity can be uncoupled from elongation rate.
Insights
RNA polymerase II (Pol II) elongation rate and processivity in vivo are affected by mutations and drugs. Reduced Pol II elongation leads to dissociation from chromatin, suggesting processivity can be uncoupled from elongation rate.
Area of Science:
- Molecular Biology
- Gene Expression
- Biochemistry
Background:
- Transcriptional elongation by RNA polymerase II (Pol II) is crucial for gene expression.
- Factors governing Pol II elongation rate and processivity in vivo remain poorly understood.
Purpose of the Study:
- To investigate the in vivo effects of mutations and drugs on Pol II elongation rate and processivity.
- To elucidate the relationship between Pol II elongation rate and processivity.
Main Methods:
- Analysis of Pol II subunit mutations (Rpb2).
- Assessment of putative elongation factors, THO complex, and Spt4 mutations.
- Treatment with drugs 6-azauracil and mycophenolic acid.
- Investigating combined effects of drugs and mutations (Spt4, TFIIS, CTDK-1).
Main Results:
- A mutation in the Rpb2 subunit of Pol II reduced both elongation rate and processivity.
- Putative elongation factors did not affect elongation rate, but THO complex and Spt4 mutations reduced processivity.
- 6-azauracil and mycophenolic acid decreased both elongation rate and processivity.
- Drug-induced processivity defects were exacerbated by mutations in Spt4, TFIIS, and CTDK-1.
Conclusions:
- Reduced Pol II elongation rate in vivo correlates with premature dissociation from the chromatin template.
- Pol II processivity can be uncoupled from its elongation rate.
- Elucidation of factors influencing Pol II dynamics during transcription.
More Related Videos
Related Concept Videos
Eukaryotic RNA Polymerases
All three eukaryotic RNAPs require specific transcription factors, of which the...
Eukaryotic RNA Polymerases
All three eukaryotic RNAPs require specific transcription factors, of which the...
Transcription Elongation Factors
The transcription elongation is regulated via pausing of RNA polymerase on several occasions during transcription. In bacteria, these halts are necessary because the transcription of DNA into mRNA is coupled to the translation of that mRNA into a...
Transcription Initiation
The promoters and enhancers and their accessory proteins allow tight regulation of...
Bacterial RNA Polymerase
In most genes, the transcription site is a single base present upstream of the coding sequence. Though RNAP is a catalytically efficient enzyme, it does not recognize...
Bacterial RNA Polymerase
In most genes, the transcription site is a single base present upstream of the coding sequence. Though RNAP is a catalytically efficient enzyme, it does not recognize...

